HRTX Heron Therapeutics Inc
7,197
$2.97
$0.16
(5.69%)
| Watchers | 7,197 |
| 52-Wk Low | $0.50 |
| 52-Wk High | $3.22 |
| Market Cap | $423.33M |
| Volume | 1.3M |
| 52-Wk High | $3.22 |
| 52-Wk Low | $0.50 |
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesPR Newswire • 8 days ago
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent...
Share to Feed
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire SAN DIEGO, April 11, 2024 SAN DIEGO...
Congress Park Capital LLC increased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 205.3% during the fourth quarter, according to its most recent filing with the...
Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report)'s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.73 and traded...
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference...
Heron Therapeutics (HRTX) has issued an update. Ira Duarte has been appointed as the new principal accounting officer of Heron Therapeutics, Inc...
Heron Therapeutics (NASDAQ:HRTX Get Free Report) had its target price raised by equities research analysts at Needham & Company LLC from $4.00 to $5.00 in a report issued on Wednesday...
This price move could indicate a change in the trend, and may be a buy signal for investors...
HRTX's total volume now sits at 17.8M. The +27.27% price change was insignificant, leaving IBM's price at $3.01...
This indicator may be signaling HRTX's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...